The added value of contrast-enhanced cardiac magnetic resonance to predict positive genetic testing in clinically suspected Lamin A/C cardiomyopathy

Background

Lamin A/C cardiomyopathy (CM) is an inherited disease due to LMNA gene mutation with particular phenotype that associates conduction disorders, frequent atrial fibrillation and life-threatening ventricular arrhythmias, with normal or altered ventricular systolic function. Cardiac magnetic resonance (CMR) studies suggest frequent late gadolinium enhancement (LGE) involving septal mid-myocardium.

Aims

To assess the added value of CMR to conventional clinical features of Lamin A/C CM for the prediction of a positive LMNA gene testing.

Methods

We performed a retrospective monocentric study in all index patients referred for genetic testing for a clinical suspicion of Lamin A/C CM. Clinical, ECG and imaging data including CMR at time of genetic testing in patients with a positive test (LMNA+) and patients without (LMNA-) were compared. The diagnostic performances of relevant parameters for the prediction of a positive LMNA gene testing were analyzed in several logistic regression models.

Results

90 patients were included (55 LMNA+, 35 LMNA-).49% had significant left ventricular (LV) dilatation on echocardiography,57% had a LV ejection fraction (LVEF)<50%, 46% had a significant left atrial dilatation, and 17% had right ventricular dysfunction. None of these parameters were different comparing LMNA+ and LMNA- patients. LMNA+ patients had significantly more frequent familial history of sudden cardiac death (SCD) or CM. There were no significant differences between LMNA+ and LMNA- patients in terms of conduction disorders, ventricular and supra-ventricular arrhythmias. The only significant difference on ECG was a more frequent abnormal R-wave progression in V1-V3 in LMNA+ patients (87.8% vs 39.4%, p<0.001). 55 patients had a CMR (28/55 LMNA+, 27/35 LMNA-). The main reason for not performing CMR was the presence of cardiac implantable electronic device. LMNA+ patients had significantly more LGE than LMNA- (20/28 (71%) vs 9/27 (33%), p=0.011). The main differences in LGE features between the 2 groups were septal involvement (70% in LMNA+ vs 11% in LMNA-, p=0.005) and mid-myocardium localization (95% vs 44%, p=0.005). In a first logistic regression model without CMR data in all 90 patients, V1-V3 R-wave abnormalities, familial history of SCD and sinus node dysfunction were independent predictors of a positive LMNA gene testing (Sensitivity 89%, specificity 46%, accuracy 72%). A second model in the 55 patients who had a CMR showed better accuracy (85%), mainly driven by increased specificity (81%) with preserved sensitivity (89%). V1-V3 R-wave abnormalities, premature ventricular contractions, non-depressed LVEF and septal LGE predicted positive LMNA gene testing in this model (Septal LGE OR=31, 95% CI 4–715; p=0.005).

Conclusion

CMR, particularly septal mid-myocardium LGE, carries good diagnostic accuracy to predict a positive LMNA gene testing in clinically suspected Lamin A/C CM with increased specificity when added to conventional red flags.

Funding Acknowledgement

Type of funding source: None

Tonate virus infection in French Guiana: clinical aspects and seroepidemiologic study

Two recent cases of human infection with Tonate virus, one of which was a fatal case of encephalitis, have renewed interest in these viruses in French Guiana. The clinical aspects of confirmed and probable cases of infection with this virus indicate that it has pathogenic properties in humans similar to those of other viruses of the Venezuelan equine encephalitis complex. To determine the prevalence of antibodies to Tonate virus in the various ethnic groups and areas of French Guiana, 3,516 human sera were tested with a hemagglutination inhibition test. Of these, 11.9% were positive for the virus, but significant differences in seroprevalence were found by age, with an increase with age. After adjustment for age, significant differences were found between places of residence. The prevalence of antibody to Tonate virus was higher in savannah areas, especially in the Bas Maroni (odds ratio [OR] = 22.2, 95% confidence interval [CI] = 15.2-32.4) and Bas Oyapock areas (OR = 13.4; 95% CI = 9.8-18.4). The ethnic differences observed in this study were due mainly to differences in place of residence, except that whites were significantly less frequently infected than other ethnic groups. This study indicates that Tonate virus infection is highly prevalent in French Guiana, especially in savannah areas.

Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure

We compared the value of plasma neurohormones and cardiopulmonary exercise testing for predicting long-term prognosis in patients with moderate congestive heart failure (CHF). We studied 264 consecutive patients with CHF due to left ventricular systolic dysfunction. Plasma atrial natriuretic peptide (ANP), norepinephrine, and endothelin-1 were measured at rest in all patients, who also underwent a symptom-limited maximal exercise with oxygen consumption (VO(2)) determination. After a median follow-up of 789 days, 52 deaths and 31 heart transplantations occurred, of which 4 were urgent. In an univariate analysis, New York Heart Association functional class, systolic blood pressure at rest, left ventricular end-diastolic diameter, left ventricular ejection fraction, peak VO(2), percent of predicted peak VO(2), plasma ANP, plasma norepinephrine, and plasma endothelin-1 were associated with survival without urgent heart transplantation. In a multivariate stepwise regression analysis, only plasma ANP (p = 0.0001), left ventricular ejection fraction (p = 0.007), and plasma norepinephrine (p = 0.035), but neither peak VO(2) nor percentage of predicted peak VO(2), were independent predictors of death or urgent heart transplantation. Determination of plasma ANP and norepinephrine provides additional independent information for long-term prognostic determination compared with exercise testing alone. Measurement of plasma neurohormones should therefore be considered routinely as a complementary or alternative tool for identifying high-risk patients with moderate CHF.